Making sound public health decisions for the roll-out of COVID-19 vaccines

Journal of Travel Medicine
Volume 28, Issue 4, May 2021
https://academic.oup.com/jtm/issue

 

Making sound public health decisions for the roll-out of COVID-19 vaccines
Priyanka, PhD, Om Prakash Choudhary,, PhD, Indraj Singh, MD
Journal of Travel Medicine, Volume 28, Issue 4, May 2021, taab031, https://doi.org/10.1093/jtm/taab031
The universal mitigation of the pandemic triggered by severe acute respiratory syndrome coronavirus 2 relies on successfully implementing a fast-paced immunization program based on an efficient framework encompassing the in-field logistics of the vaccine distribution, coverage and efficacy. The forthcoming challenges and resolution plans for executing the coronavirus disease 2019 vaccination have been comprehensively outlined in the present discourse.

What must be done to tackle vaccine hesitancy and barriers to COVID-19 vaccination in migrants?

Journal of Travel Medicine
Volume 28, Issue 4, May 2021
https://academic.oup.com/jtm/issue

 

What must be done to tackle vaccine hesitancy and barriers to COVID-19 vaccination in migrants?
Alison F Crawshaw, MSc, Anna Deal, MSc, Kieran Rustage, MPhil, Alice S Forster, PhD, Ines Campos-Matos, MD, PhD …
Journal of Travel Medicine, Volume 28, Issue 4, May 2021, taab048, https://doi.org/10.1093/jtm/taab048
Migrants have been disproportionately impacted by COVID-19 and emerging evidence suggests they may face barriers to COVID-19 vaccination. Participatory approaches and engagement strategies are urgently needed to strengthen uptake, alongside innovative delivery mechanisms and sharing of best practice, to ensure migrants are better consider within countries’ existing vaccine priority structures.

Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2

Journal of Travel Medicine
Volume 28, Issue 4, May 2021
https://academic.oup.com/jtm/issue

 

Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2
Gajanan N Sapkal, PhD, Pragya D Yadav, PhD, Raches Ella, MS, Gururaj R Deshpande, PhD, Rima R Sahay, MD …
Journal of Travel Medicine, Volume 28, Issue 4, May 2021, taab051,

Changes in the incidence of invasive disease due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data

Lancet Digital Health
Jun 2021 Volume 3 Number 6 e330-e407
https://www.thelancet.com/journals/landig/issue/current

 

Articles
Changes in the incidence of invasive disease due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data
Angela B Brueggemann, et al

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Lancet Infectious Diseases
Jun 2021 Volume 21 Number 6 p743-888, e141-e181
https://www.thelancet.com/journals/laninf/issue/current

 

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
Zhiwei Wu, et al.

Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial

Lancet Infectious Diseases
Jun 2021 Volume 21 Number 6 p743-888, e141-e181
https://www.thelancet.com/journals/laninf/issue/current

 

Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial
Ed Clarke, et al.
Open Access

Effects of different types of written vaccination information on COVID-19 vaccine hesitancy in the UK (OCEANS-III): a single-blind, parallel-group, randomised controlled trial

Lancet Public Health
Jun 2021 Volume 6 Number 6 e346-e433
https://www.thelancet.com/journals/lanpub/issue/current

 

Articles
Effects of different types of written vaccination information on COVID-19 vaccine hesitancy in the UK (OCEANS-III): a single-blind, parallel-group, randomised controlled trial
Daniel Freeman, et al.

A global public health convention for the 21st century

Lancet Public Health
Jun 2021 Volume 6 Number 6 e346-e433
https://www.thelancet.com/journals/lanpub/issue/current

 

Health Policy
A global public health convention for the 21st century
Johnathan H Duff, et al
Summary
As shown by COVID-19, infectious diseases with a pandemic potential present a grave threat to health and wellbeing. Although the International Health Regulations provide a framework of binding legal obligations for pandemic prevention, preparedness, and response, many countries do not comply with these regulations. There is a need for a renewed framework for global collective action that ensures conformity with international regulations and promotes effective prevention and response to pandemic infectious diseases. This Health Policy identifies the necessary characteristics for a new global public health security convention designed to optimise prevention, preparedness, and response to pandemic infectious diseases. We propose ten recommendations to strengthen global public health governance and promote compliance with global health security regulations. Recommendations for a new global public health security convention include greater authority for a global governing body, an improved ability to respond to pandemics, an objective evaluation system for national core public health capacities, more effective enforcement mechanisms, independent and sustainable funding, representativeness, and investment from multiple sectors, among others. The next steps to achieve these recommendations include assembling an invested alliance, specifying the operational structures of a global public health security system, and overcoming barriers such as insufficient political will, scarcity of resources, and individual national interests.

Will SARS-CoV-2 variants of concern affect the promise of vaccines?

Nature Reviews Immunology
Volume 21 Issue 6, June 2021
https://www.nature.com/nri/volumes/21/issues/6

 

Comment | 29 April 2021
Will SARS-CoV-2 variants of concern affect the promise of vaccines?
This Comment discusses how the emerging SARS-CoV-2 variants of concern could impact on the hopes of long-term pandemic control through vaccination and the mutations that might be relevant to the design of modified vaccines.
Ravindra K. Gupta

Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection

Nature Reviews Immunology
Volume 21 Issue 6, June 2021
https://www.nature.com/nri/volumes/21/issues/6

 

Perspective | 29 April 2021
Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection
The duration of immunity to coronavirus disease 2019 (COVID-19) from prior infection and longer-term risk of reinfection are currently unclear. Cromer and colleagues discuss the immune control of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the implications of this for the future control of the pandemic.
Deborah Cromer, Jennifer A. Juno, Miles P. Davenport

ENABLE: an engine for European antibacterial drug discovery and development

Nature Reviews Drug Discovery
Volume 20 Issue 6, June 2021
https://www.nature.com/nrd/volumes/20/issues/6

 

Comment | 04 May 2021
ENABLE: an engine for European antibacterial drug discovery and development
ENABLE is an antibacterial drug discovery and development consortium formed as a public–private partnership in 2014 as part of the Innovative Medicines Initiative (IMI) New Drugs for Bad Bugs (ND4BB) programme. With the project soon ending, here we provide a brief overview and reflect on its achievements, strengths and weaknesses.
Marie Olliver, Laura Griestop, Anders Karlén

Emerging concepts in the science of vaccine adjuvants

Nature Reviews Drug Discovery
Volume 20 Issue 6, June 2021
https://www.nature.com/nrd/volumes/20/issues/6

 

Review Article | 06 April 2021
Emerging concepts in the science of vaccine adjuvants
This Review discusses how recent advances in understanding the activation of the innate immune system are shedding light on the immunological mechanisms of action of adjuvants and highlights how systems-based approaches are beginning to revitalize adjuvant design and development.
Bali Pulendran, Prabhu S. Arunachalam, Derek T. O’Hagan

Global economic costs due to vivax malaria and the potential impact of its radical cure: A modelling study

PLoS Medicine
http://www.plosmedicine.org/
(Accessed 5 Jun 2021)

 

Global economic costs due to vivax malaria and the potential impact of its radical cure: A modelling study
Angela Devine, Katherine E. Battle, Niamh Meagher, Rosalind E. Howes, Saber Dini, Peter W. Gething, Julie A. Simpson, Ric N. Price, Yoel Lubell
Research Article | published 01 Jun 2021 PLOS Medicine
https://doi.org/10.1371/journal.pmed.1003614

In science we (should) trust: Expectations and compliance across nine countries during the COVID-19 pandemic

PLoS One
http://www.plosone.org/
[Accessed 5 Jun 2021]

 

In science we (should) trust: Expectations and compliance across nine countries during the COVID-19 pandemic
Cristina Bicchieri, Enrique Fatas, Abraham Aldama, Andrés Casas, Ishwari Deshpande, Mariagiulia Lauro, Cristina Parilli, Max Spohn, Paula Pereira, Ruiling Wen
Research Article | published 04 Jun 2021 PLOS ONE
https://doi.org/10.1371/journal.pone.0252892

Influenza vaccine community outreach: Leveraging an interprofessional healthcare student workforce to immunize marginalized populations

Preventive Medicine
Volume 147 June 2021
https://www.sciencedirect.com/journal/preventive-medicine/vol/147/suppl/C

 

Research article only
Influenza vaccine community outreach: Leveraging an interprofessional healthcare student workforce to immunize marginalized populations
Sarah H. Brown, Emilie L. Fisher, Alexandra Q. Taylor, Kevin E. Neuzil, … Robert F. Miller
Article 106460

Links between conspiracy beliefs, vaccine knowledge, and trust: Anti-vaccine behavior of Serbian adults

Social Science & Medicine
Volume 277 May 2021
https://www.sciencedirect.com/journal/social-science-and-medicine/vol/277/suppl/C

 

Research article Abstract only
Links between conspiracy beliefs, vaccine knowledge, and trust: Anti-vaccine behavior of Serbian adults
J. Milošević Đorđević, S. Mari, M. Vdović, A. Milošević
Article 113930

Global, regional and national disability-adjusted life years due to HIV from 1990 to 2019: findings from the Global Burden of Disease Study 2019

Tropical Medicine & International Health
Volume 26, Issue 6 Pages: i-iv, 609-714 June 2021
https://onlinelibrary.wiley.com/toc/13653156/current

 

Original Research Papers
Global, regional and national disability-adjusted life years due to HIV from 1990 to 2019: findings from the Global Burden of Disease Study 2019
Jiayuan Wu, Tianwen Lai, Huanqin Han, Jie Liu, Shuangmiao Wang, Jun Lyu
Pages: 610-620
First Published: 27 February 2021

Rotavirus disease and health care utilisation among children under 5 years of age in highly developed countries: A systematic review and meta-analysis

Vaccine
Volume 39, Issue 22 Pages 2907-3102 (21 May 2021)
https://www.sciencedirect.com/journal/vaccine/vol/39/issue/22

 

Review article Open access
Rotavirus disease and health care utilisation among children under 5 years of age in highly developed countries: A systematic review and meta-analysis
Cristina Ardura-Garcia, Christian Kreis, Milenko Rakic, Manon Jaboyedoff, … Claudia E. Kuehni
Pages 2917-2928

Effective interventions to increase routine childhood immunization coverage in low socioeconomic status communities in developed countries: A systematic review and critical appraisal of peer-reviewed literature

Vaccine
Volume 39, Issue 22 Pages 2907-3102 (21 May 2021)
https://www.sciencedirect.com/journal/vaccine/vol/39/issue/22

 

Review article Abstract only
Effective interventions to increase routine childhood immunization coverage in low socioeconomic status communities in developed countries: A systematic review and critical appraisal of peer-reviewed literature
Amanda Alberga Machado, Sarah A. Edwards, Melissa Mueller, Vineet Saini
Pages 2938-2964

Within-country age-based prioritisation, global allocation, and public health impact of a vaccine against SARS-CoV-2: A mathematical modelling analysis

Vaccine
Volume 39, Issue 22 Pages 2907-3102 (21 May 2021)
https://www.sciencedirect.com/journal/vaccine/vol/39/issue/22

 

Research article Open access
Within-country age-based prioritisation, global allocation, and public health impact of a vaccine against SARS-CoV-2: A mathematical modelling analysis
Alexandra B. Hogan, Peter Winskill, Oliver J. Watson, Patrick G.T. Walker, … Azra C. Ghani
Pages 2995-3006

Transmission of Vaccination Attitudes and Uptake Based on Social Contagion Theory: A Scoping Review

Vaccines — Open Access Journal
http://www.mdpi.com/journal/vaccines

 

(Accessed 5 Jun 2021)
Open Access Review
Transmission of Vaccination Attitudes and Uptake Based on Social Contagion Theory: A Scoping Review
by Pinelopi Konstantinou et al.
Vaccines 2021, 9(6), 607; https://doi.org/10.3390/vaccines9060607 (registering DOI) – 05 Jun 2021
Abstract
Vaccine hesitancy is a complex health problem, with various factors involved including the influence of an individual’s network. According to the Social Contagion Theory, attitudes and behaviours of an individual can be contagious to others in their social networks. This scoping review aims […]

Knowledge, Attitudes and Practices (KAP) toward the COVID-19 Vaccine in Oman: A Pre-Campaign Cross-Sectional Study

Vaccines — Open Access Journal
http://www.mdpi.com/journal/vaccines

 

Open Access Article
Knowledge, Attitudes and Practices (KAP) toward the COVID-19 Vaccine in Oman: A Pre-Campaign Cross-Sectional Study
by Sabria Al-Marshoudi et al
Vaccines 2021, 9(6), 602; https://doi.org/10.3390/vaccines9060602 (registering DOI) – 04 Jun 2021
Abstract
Oman is globally acknowledged for its well-structured immunization program with high vaccination coverage. The massive spread of misinformation brought on by the COVID-19 pandemic, as well as the easy access to various media channels, may affect acceptance of a vaccine, despite the inherent […]

Lack of Trust, Conspiracy Beliefs, and Social Media Use Predict COVID-19 Vaccine Hesitancy

Vaccines — Open Access Journal
http://www.mdpi.com/journal/vaccines

 

Open Access Article
Lack of Trust, Conspiracy Beliefs, and Social Media Use Predict COVID-19 Vaccine Hesitancy
by Will Jennings et al.
Vaccines 2021, 9(6), 593; https://doi.org/10.3390/vaccines9060593 – 03 Jun 2021
Abstract
As COVID-19 vaccines are rolled out across the world, there are growing concerns about the roles that trust, belief in conspiracy theories, and spread of misinformation through social media play in impacting vaccine hesitancy. We use a nationally representative survey of 1476 adults […]

Challenges and Opportunities of Mass Vaccination Centers in COVID-19 Times: A Rapid Review of Literature

Vaccines — Open Access Journal
http://www.mdpi.com/journal/vaccines

 

Open Access Review
Challenges and Opportunities of Mass Vaccination Centers in COVID-19 Times: A Rapid Review of Literature
by Vincenza Gianfredi et al.
Vaccines 2021, 9(6), 574; https://doi.org/10.3390/vaccines9060574 – 01 Jun 2021
Abstract
A mass vaccination center is a location, normally used for nonhealthcare activities, set up for high-volume and high-speed vaccinations during infectious disease emergencies. The high contagiousness and mortality of COVID-19 and the complete lack of population immunity posed an extraordinary threat for global […]

Media/Policy Watch

Media/Policy Watch
This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. Media Watch is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from Journal Watch above which scans the peer-reviewed journal ecology.
We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.
The sheer volume of vaccine and pandemic-related coverage is extraordinary. We will strive to present the most substantive analysis and commentary we encounter.

 

The Atlantic
http://www.theatlantic.com/magazine/
Accessed 5 Jun 2021
[No new, unique, relevant content]

 

BBC
http://www.bbc.co.uk/
Accessed 5 Jun 2021
[No new, unique, relevant content]

 

The Economist
http://www.economist.com/
Accessed 5 Jun 2021
[No new, unique, relevant content]

 

Financial Times
https://www.ft.com/
Accessed 5 Jun 2021
[No new, unique, relevant content]
Top of Form
Bottom of Form

 

Forbes
http://www.forbes.com/
Accessed 5 Jun 2021
Jun 5, 2021, 2021
Royal Caribbean Won’t Require Covid-19 Vaccination To Ride U.S. Cruises
Florida Governor Ron DeSantis recently signed a law that could charge cruise ship operators $5,000 every time they require a person to provide proof of vaccination to board a cruise ship.
By Bruce Y. Lee Senior Contributor

Covid Is Still Surging In These Countries Amid Uneven Vaccine Rollout
Covid cases have tripled in Argentina and octupled in Malaysia over the last two months.
By Joe Walsh Forbes Staff

 

Foreign Affairs
http://www.foreignaffairs.com/
Accessed 5 Jun 2021
Snapshot June 4, 2021
COVID’s Haves and Have-Nots
Vaccinating the world will be arduous and expensive, but there is no time to waste.
Rajiv J. Shah

 

Foreign Policy
http://foreignpolicy.com/
Accessed 5 Jun 2021[No new, unique, relevant content]

 

New Yorker
http://www.newyorker.com/
Accessed 5 Jun 2021
Annals of Technology
The Peril of Not Vaccinating the World
Absent a concerted global commitment to vaccine equity, the virus will continue to evolve, and humanity may be consigned to a never-ending pandemic.
By Sue Halpern
June 3, 2021

 

New York Times
http://www.nytimes.com/
Accessed 5 Jun 2021
Africa
The coronavirus surges across Africa as vaccine programs flounder.
The W.H.O. said that test positivity had risen in 14 countries on the African continent over the last seven days, and that eight had reported surges of over 30 percent in new cases.
By Abdi Latif Dahir

World
India’s top court criticizes Narendra Modi’s government for a sluggish vaccination program.
By Suhasini Raj and Mujib Mashal

 

Washington Post
https://www.washingtonpost.com/
Accessed 5 Jun 2021
[No new, unique, relevant content]

Think Tanks et al

Think Tanks et al

Brookings
http://www.brookings.edu/
Accessed 5 Jun 2021
[No new digest content]
 
 
Center for Global Development [to 5 Jun 2021]
http://www.cgdev.org/page/press-center
Review
Should Donated COVID-19 Vaccines Count as ODA?
June 4, 2021
The benefits to expanded vaccination programs in low- and middle-income countries (LMICs) simply dwarf the cost. Rich countries should be donating more vaccines faster to poorer countries. It is difficult to think of a more urgent global priority and it is surely a best buy in international development.
Charles Kenny

How Much Do We Know about COVID-19 Vaccine Deals? The Quest for Transparent and Equitable Vaccine Deployment
Event 6/16/21
Policymakers around the world have made the expeditious deployment of safe and effective COVID-19 vaccines a top priority in order to bring the pandemic under control. But how much information about COVID-19 purchasing agreements is actually available in the public domain? And how can data sharing and contract publication help policymakers decide how much vaccine countries should buy, who should pay, and how they should be delivered and distributed?
 
 
Chatham House [to 5 Jun 2021]
https://www.chathamhouse.org/
Accessed 5 Jun 2021
[No new digest content]

 
 
CSIS
https://www.csis.org/
Accessed 5 Jun 2021
Podcast Episode
Improving Health Equity in the Covid-19 Pandemic and Beyond
June 2, 2021 | By Katherine E. Blis

 
 

Kaiser Family Foundation
https://www.kff.org/search/?post_type=press-release
Accessed 5 Jun 2021
June 3, 2021 News Release
Two-Thirds of the Public Say the U.S. Should Play a Major Role in Distributing COVID-19 Vaccines Globally, But Not Most Republicans
With increased attention to the global need for COVID-19 vaccines and the Biden administration’s announcement today about how it plans to distribute the first portion of the 80 million doses it will share by the end of this month, the latest KFF Health Tracking Poll finds that two-thirds of the…
 
 
World Economic Forum [to 5 Jun 2021]
https://agenda.weforum.org/news/
Media
June 3, 2021 News Release
Two-Thirds of the Public Say the U.S. Should Play a Major Role in Distributing COVID-19 Vaccines Globally, But Not Most Republicans
With increased attention to the global need for COVID-19 vaccines and the Biden administration’s announcement today about how it plans to distribute the first portion of the 80 million doses it will share by the end of this month, the latest KFF Health Tracking Poll finds that two-thirds of the…

Vaccines and Global Health: The Week in Review :: 29 May 2021

Vaccines and Global Health: The Week in Review is a weekly digest  summarizing news, events, announcements, peer-reviewed articles and research in the global vaccine ethics and policy space. Content is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage. You are viewing the blog version of our weekly digest, typically comprised of between 30 and 40 posts below all dated with the current issue date

.– Request an Email Summary: Vaccines and Global Health : The Week in Review is published as a single email summary, scheduled for release each Saturday evening before midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

– pdf version:  A pdf of the current issue is available here: 

– blog edition: comprised of the approx. 35+ entries posted below.

– Twitter:  Readers can also follow developments on twitter: @vaxethicspolicy.
.
– Links:  We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

.
David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy

Seventy-fourth World Health Assembly #WHA74

Milestones :: Perspectives :: Research

 

World Health Assembly

Seventy-fourth World Health Assembly #WHA74
24 May to 1 June 2021
Theme: Ending this pandemic, preventing the next: building together a healthier, safer and fairer world.
:: Provisional agenda
:: Watch live WHA74 sessions
:: Documents

 

::::::

Double COVID-19 Vaccine Production, Bolster Primary Health-Care Systems to Prepare for Next Global Emergency, Secretary-General Tells World Health Assembly
24 May 2021 SG/SM/20740
[Excerpt focused on COVID vaccines/vaccination]
…We are at war with a virus.  We need the logic and urgency of a war economy, to boost the capacity of our weapons.  On Friday, I called on the [Group of 20] (G20) to set up a task force that brings together all countries with vaccine production capacities, the World Health Organization, the ACT-Accelerator partners and international financial institutions, able to deal with the pharmaceutical companies and other key stakeholders.
It should aim to at least double manufacturing capacity by exploring all options, from voluntary licenses and technology transfers to patent pooling and flexibility on intellectual property rights.  The task force should address equitable global distribution by using the ACTAccelerator and its COVAX Facility.  The G20 task force should be co-convened at the highest levels by the major Powers who hold most of the global supply and production capacity, together with the multilateral system.  I am ready to mobilize the entire United Nations system to support this effort…

 

::::::

Director-General’s opening remarks at the World Health Assembly – 24 May 2021
[Excerpt focused on COVID vaccines/vaccination]
…The ongoing vaccine crisis is a scandalous inequity that is perpetuating the pandemic. More than 75% of all vaccines have been administered in just 10 countries. There is no diplomatic way to say it: a small group of countries that make and buy the majority of the world’s vaccines control the fate of the rest of the world.

The number of doses administered globally so far would have been enough to cover all health workers and older people, if they had been distributed equitably. We could have been in a much better situation.

I understand that every government has a duty to protect its own people. I understand that every government wants to vaccinate its entire population. That’s what we want too. And in time, there will be enough supply for everyone, including those at lower risk.

But right now, there is not enough supply. Countries that vaccinate children and other low-risk groups now do so at the expense of health workers and high-risk groups in other countries. That’s the reality.

At the Executive Board meeting in January, I issued a challenge to see vaccination of health workers and older people underway in all countries within the first 100 days of the year. That target was very nearly achieved. But the number of doses available to COVAX remains vastly inadequate.

COVAX works. We have shipped every single one of the 72 million doses we have been able to get our hands on so far to 125 countries and economies. But those doses are sufficient for barely 1 percent of the combined population of those countries.

So today I am calling on Member States to support a massive push to vaccinate at least 10 percent of the population of every country by September, and a “drive to December” to achieve our goal of vaccinating at least 30 percent by the end of the year. This is crucial to stop severe disease and death, keep our health workers safe and reopen our societies and economies.

Sprinting to our September goal means we must vaccinate 250 million more people in low- and middle-income countries in just four months, including all health workers and the most at-risk groups as the first priority. These are the minimum targets we should aim for.

At the G20 Global Health Summit on Friday, IMF Managing Director Kristalina Georgieva proposed vaccinating 40 percent of the world’s population by the end of the year and 60 percent by mid-2022.
We are in discussions with the IMF, Member States and our partners about how to make these ambitious targets achievable.

 

Here’s how the “Drive to December” must happen:
First, share doses through COVAX, now. I welcome the commitments made by Member States to donate doses, including the important announcements made at the G20 Global Health Summit on Friday.

But to achieve the goals for September and the end of the year, we need hundreds of millions more doses, we need them to go through COVAX, and we need them to start moving in early June.
Manufacturers must play their part, by ensuring any country that wants to share doses through COVAX can do it within days, not months.

I call on all manufacturers to give COVAX first right of refusal on new volume of vaccines, or to commit 50% of their volumes to COVAX this year. And we need every country that receives vaccines to use them as quickly as possible. No dose can lay idle, or worse, be thrown away. Country-level preparations to reach their populations must move as fast as vaccines.

Second, scale-up manufacturing. The bottom line is that we need a lot more doses, we need them fast, and we must leave no stone unturned to get them. Several manufacturers have said they have capacity to produce vaccines if the originator companies are willing to share licenses, technology and know-how. I find it difficult to understand why this has not happened yet.

I thank India and South Africa for their initiative at the World Trade Organization to waive intellectual property protections for COVID-19 products, and I thank those countries that are supporting these efforts. And we urge Member States and manufacturers to join C-TAP, the WHO COVID-19 Technology Access Pool, which provides a powerful mechanism for sharing licenses in a non-exclusive, transparent way. I thank Prime Minister Pedro Sanchez for his commitment that Spain will join C-TAP, and we expect more good news in the coming days.

And third, fully fund the ACT Accelerator. There remains an 18.5 billion US dollar gap in the ACT Accelerator.

Ultimately, the pandemic has shown clearly that in an emergency, low and lower-middle income countries cannot rely on imports from vaccine-producing countries. I welcome the draft resolution on strengthening local production of medicines and other health technologies that Member States will consider at this Assembly.

I would also like to take this opportunity to express my deep appreciation to President Biden for reversing the decision to take the United States out of WHO, for donating US$4 billion to COVAX, and also for their announcement that they will donate 80 million vaccine doses globally – these are the largest contributions announced – and for supporting the intellectual property waiver…

 

::::::

Update from the Seventy-fourth World Health Assembly – 29 May 2021
29 May 2021 News release
New resolutions on:
:: Local production of medicines
:: Ending violence against children
:: Addressing social determinants of health

Strengthening local production of medicines and other health technologies to improve access
Member State requests for WHO’s support in strengthening local production have been increasing in recent years. The COVID-19 pandemic has only served to highlight even more the urgent need for enhancing quality manufacturing capacity in all regions of the world, including for innovative, highly effective health products such as mRNA technologies. Such capacity is necessary to address or even avert future public health emergencies and to improve access to health products in general through stronger health systems.
Sponsored by more than 100 countries, today’s resolution specifically calls for a more comprehensive, all-of-government approach, national strategies and action plans, an enabling business environment, human capital development, multi-stakeholder collaboration and engagement in regional and global networks.
WHO has already committed to holding the first ever World Local Production Forum in June this year, convening countries, partners and other stakeholders to discuss strategies to promote local production to improve access to health products during the current pandemic and beyond…

Tackling social determinants of health
…The resolution aims to strengthen action globally and within countries on the social determinants of health; to reduce health inequities by involving all sectors in taking concrete action to improve living conditions and reduce social inequalities; and improve monitoring of social determinants and health inequities. The resolution lists actions to be taken by governments, civil society, international organizations, intergovernmental organizations, the private sector and the WHO Secretariat, including in continuing efforts to combat the COVID-19 pandemic and in future recovery efforts.

Update from the Seventy-fourth World Health Assembly – 28 May 2021
28 May 2021 News release
:: New resolutions on the health and care workforce and strategic directions for nursing and midwifery
:: Decisions on patient safety; health, environment and climate change; chemicals management; coordination of work on noncommunicable diseases
:: Global Action Plan for Healthy Lives and Wellbeing for All
:: Prevention of sexual exploitation, abuse and harassment

World Health Assembly adopts new resolution on malaria
28 May 2021 Departmental news
The World Health Assembly, the main governing body of the World Health Organization, has adopted a new resolution that aims to revitalize and accelerate efforts to end malaria, a preventable and treatable disease that continues to claim more than 400 000 lives annually…
The resolution urges Member States to step up the pace of progress through plans and approaches that are consistent with WHO’s updated global malaria strategy and the WHO Guidelines for malaria. It calls on countries to extend investment in and support for health services, ensuring no one is left behind; sustain and scale up sufficient funding for the global malaria response; and boost investment in the research and development of new tools…

Update from the Seventy-fourth World Health Assembly – 27 May 2021
27 May 2021 News release
:: New resolutions on diabetes, health for people with disabilities; malaria; oral health
:: Decisions on eye care; HIV, Hepatitis and STIs; neglected tropical diseases, noncommunicable diseases
:: WHO programme budget approved 2022-2023

IOAC statement at the Seventy-fourth World Health Assembly, 25 May 2021
Independent Oversight and Advisory Committee for the WHO Health Emergencies Programme – IOAC
25 May 2021 Statement